Rationale: Pulmonary embolism (PE) decreases the exhaled end-tidal ratio of carbon dioxide to oxygen (etCO 2 /O 2 ). Objectives: To test if the etCO 2 /O 2 can produce clinically important changes in the probability of segmental or larger PE on computerized tomography multidetector-row pulmonary angiography (MDCTPA) in a moderate-risk population with a positive D-dimer. Methods: Emergency department and hospitalized patients with one or more predefined symptoms or signs, one or more risk factors for PE, and 64-slice MDCTPA enrolled from four hospitals. D-dimer greater than 499 ng/ml was test (1), and D-dimer less than 500 ng/ml was test(2). The median etCO 2 /O 2 less than 0.28 from seven or more breaths was test(1) and etCO 2 /O 2 greater than 0.45 was test(2). MDCTPA images were read by two independent radiologists and the criterion standard was the interpretation of acute PE by either reader. PE size was then graded. Measurements and Main Results: We enrolled 495 patients, including 60 (12%) with segmental or larger, and 29 (6%) with subsegmental PE. A total of 367 (74%) patients were D-dimer(1), including all 60 with segmental or larger PE (posterior probability 16%). The combination of D-dimer(1) and etCO 2 /O 2 (1) increased the posterior probability of segmental or larger PE to 28% (95% confidence interval [CI] for difference of 12%, 3.0-22%). The combination of D-dimer(1) and etCO 2 /O 2 (2) was observed in 40 patients (8%; 95% CI, 6-11%), and none (0/40; 95% CI, 0-9%) had segmental or larger PE on MDCTPA. No strategy changed the prevalence of subsegmental PE. Conclusions: In moderate-risk patients with a positive D-dimer, the et etCO 2 /O 2 less than 0.28 significantly increases the probability of segmental or larger PE and the etCO 2 /O 2 greater than 0.45 predicts the absence of segmental or larger PE on MDCTPA. Clinical trial registered with www.clinicaltrials.gov (NCT 00368836).
Multidetector-row computerized tomographic pulmonary angiography (MDCTPA) has become a mainstay in diagnosis and exclusion of acute pulmonary embolism (PE). Reasons for its widespread adoption may include the perception of superior diagnostic and operational test performance compared with ventilation-perfusion lung scanning and the ability to show alternative diseases (1) . However, clinical trials have not found superior outcome to MDCTPA compared with VQ scanning, and MDCTPA imparts a higher lifetime risk of cancer from radiation exposure and contrast nephropathy. The increasing resolution afforded by 64-head computed tomography (CT) equipment has produced a concomitant increase in the frequency of PE diagnosis based on an isolated subsegmental filling defect (2) (3) (4) (5) (6) (7) . The finding of an isolated subsegmental PE on MDCTPA in the absence of a deep venous thrombosis (DVT) confers significant diagnostic and therapeutic uncertainty. The diagnostic uncertainty arises from the low interobserver agreement between two radiologists for the interpretation of isolated subsegmental PE (6) (7) (8) . The therapeutic uncertainty arises from the fact that many clinicians and authors believe that patients with isolated subsegmental PE do not benefit from anticoagulation, although no clinical trial has tested this hypothesis (5, 9) . In contrast, published guidelines recommend immediate heparin anticoagulation for patients with moderate to high suspicion of segmental or larger PE and no contraindications to anticoagulation (10, 11) .
Acute PE that obstructs a segmental or larger pulmonary artery increases the volume of alveolar dead space in the lung to an extent that can be measured. The alveolar dead space can be estimated by simultaneously measuring the exhaled CO 2 and arterial blood partial pressure of CO 2 (12) . The alveolar dead space can significantly improve the diagnostic performance of the D-dimer as a screening tool for PE in the emergency department (ED) setting (12) (13) (14) (15) . However, the requirement
AT A GLANCE COMMENTARY Scientific Knowledge on the Subject
Pulmonary embolism (PE) that obstructs a segmental or larger pulmonary artery increases alveolar dead space, which leads to decreased exhaled CO 2 . The combination of alveolar dead space plus D-dimer has been found to accurately screen for acute pulmonary embolism. However, current methods of assessing alveolar dead space require arterial blood sampling.
What This Study Adds to the Field
This study tests the diagnostic accuracy of a purely breathbased, novel device that simultaneously measures exhaled CO 2 /O 2 ratio, as a noninvasive method to assess increased alveolar dead space with segmental or larger PE. This measurement does not require arterial blood sampling. The combination of either a normal etCO 2 /O 2 or a normal D-dimer is associated with a very low rate of segmental or larger PE.
for simultaneous, steady-state measurement of exhaled CO 2 and arterial blood CO 2 represents a technical challenge and causes pain to the patient. Accordingly, a purely breath-based test that does not require a simultaneous blood sample would have advantages. Patients with PE large enough to elevate the alveolar dead space exhale breaths that are more like ambient air-dilute in CO 2 and higher in O 2 -when compared with patients who have normal pulmonary ventilation-perfusion or ventilation-perfusion mismatch caused by obstruction of the airways. Several studies have found that a low exhaled, endtidal (et) CO 2 measurement increases, and a normal or high etCO 2 decreases, the probability of acute PE in symptomatic patients previously selected for PE evaluation (16, 17) . Kline and Hogg reported the end-tidal ratio of CO 2 /O 2 had an advantage over the etCO 2 alone for the detection of acute PE (18) .
This study was conducted to test the incremental change in posterior probability of PE produced by adding the etCO 2 /O 2 to the high-sensitivity, quantitative D-dimer (,500 ng/ml normal) as a screening battery for patients with suspected PE. The a priori, explicitly defined primary efficacy aims were to measure the posterior probability of PE for the D-dimer test alone compared with the following test combinations: (1) the D-dimer greater than 499 ng/ml and etCO 2 /O 2 less than 0.28, and (2) the D-dimer less than 500 ng/ml or an etCO 2 /O 2 greater than 0.45. We hypothesized that the addition of etCO 2 /O 2 to the D-dimer would significantly increase the posterior probability of PE and increase the proportion of patients who could have segmental or larger PE ruled out before MDCTPA.
Some of the results of this study have been previously reported in the form of an abstract (19) and in a published report (7) .
METHODS

Study Design
This was a prospective, four-center noninterventional, Food and Drug Administration-regulated study of diagnostic accuracy of a proprietary device conducted in accordance with the guidelines set out by the Standards for Reporting of Diagnostic Accuracy criteria (20) .
Study Setting and Population
Prospective enrollment occurred from EDs, wards, and intensive care units of four academic medical centers in the United States (see online supplement).
Because MDCTPA scans at the four sites were ordered in equal proportions from the ED as for admitted inpatients, we enrolled patients in approximately a 1:1 ratio from each location. Inclusion criteria required that an MDCTPA be ordered as standard care, and the patient had to have both one or more of 15 predefined signs or symptoms of PE and one or more of 21 predefined known risk factors for PE (see Table E1 in the online supplement) (7). All patients had to provide written informed consent. Patients were excluded if they could not provide follow-up or if they were incarcerated, pregnant, hemodynamically unstable, unable to breathe through their mouth, had fibrinolytic treatment within 48 hours, had PE diagnosed within the last 6 months and were on anticoagulation or had a history of noncompliance with anticoagulation for PE, or had known active tuberculosis.
Study Protocol
MDCTPA images were obtained at each site as part of standard care, and were done on 64-slice multidetector equipment with less than or equal to 2.5 mm collimation. Details of image acquisition and interpretation have been described (7) . Breath and blood collection. Breath and blood collection had to be completed within 24 hours of MDCTPA completion in accordance with standard operating procedures contained in the study binder.
Breath was collected and the etCO 2 /O 2 analyzed using the Breathscreen PE device, which used a computer algorithm to examine each breath in real time to reject breaths with an alveolar volume less than 100 ml or less than 150% of the airway dead space volume (21) . Seven accepted breaths were required for per-protocol analysis. Blood was analyzed for D-dimer (VIDAS ELISA; bioMerieux, Durham, NC) using FDA-cleared devices (see online supplement).
MDCTPA interpretation. Images were interpreted by two independent radiologists who were blinded to each other's interpretations (7) . Images were interpreted as ''No PE,'' ''Positive for acute PE,'' ''Positive for chronic PE,'' ''Positive for other finding,'' or ''Indeterminate.'' All scans read as positive for PE were further evaluated for the percentage obstruction of the vessel(s) using the modified method of Mastora and colleagues; PE was considered subsegmental for a total percentage lung obstruction of less than 5% (22) (see online supplement).
Criterion standard for acute PE. For the first analysis, the criterion standard defined PE as present for any MDCTPA interpreted as positive for acute PE by either or both radiologists together with clinical decision to initiate and maintain anticoagulation. In the per protocol analysis, the criterion standard for PE(1) was the interpretation of a segmental or larger filling defect on MDCTPA(2).
Follow-up
Using previously described methods (23), we used a standardized telephone survey to participants supplemented by review of updated medical records to determine if any patients developed new PE or DVT within 45 days after enrollment.
Data Analysis
The per-protocol primary efficacy aims were to measure the change in posterior probability of PE when the etCO 2 Figure 1 shows the flow diagram of patients starting with those subjects screened for inclusion to the point of final outcome with respect to PE diagnosis. A total of 547 patients signed a consent form and 495 had complete data. Exclusions included 9 patients for whom a blood specimen could not be obtained, 7 other patients for whom seven accepted breaths could not be obtained, and 11 other patients with missing blood and breath samples. All 495 patients with complete data had both the Ddimer assay performed and the etCO 2 /O 2 measurement performed. Breaths were collected in an average of 45 6 14 seconds and etCO 2 /O 2 data are based on an average of 10.5 6 2.6 breaths. General demographic characteristics and clinical characteristics of patients are shown in Table 1 .
RESULTS
The criterion standard for acute PE was found in 89 MDCTA scans (either reader interpreted acute PE); chronic PE was found in 4 others in the absence of any findings suggestive of acute PE. Twenty-nine of 89 (32.5%) MDCTPA scans demonstrated acute PE that was subsegmental. The mean pulmonary vascular obstruction was 19.7 6 23.6% for the 89 scans with acute PE interpretations and 6.8 6 5.0% for the four scans with chronic PE (see online supplement).
Compared with those without PE, patients with PE(1) had significantly higher mean D-dimer (3,566 6 4,103 ng/ml [PE (1) Detection of Any Acute PE Table 2 shows the diagnostic indexes and posterior probabilities of PE that would have been produced by the D-dimer, etCO 2 / O 2 alone, and the combinations of these tests using the first criterion standard. This table considers all 89 PE(1) scans as criterion positive, including 29 MDCTPA scans with subsegmental-sized filling defects. The D-dimer was positive in 367 (74%) of the cohort, including 85 patients with PE, leading to a posterior probability of PE of 23.2% (95% confidence interval [CI], 18.9-27.8%) for a positive D-dimer. The D-dimer was negative in 128/495 (26%; 95% CI, 18.3-25.0%), including four patients with PE, leading to a posterior probability of 3.1% (95% CI, 0.9-7.8%). These four had isolated subsegmental PE. The addition of the etCO 2 /O 2 to the D-dimer increased the posterior probability of PE with a positive test result, and expanded the proportion of the cohort with a negative test result. First, from the 367 patients with a positive D-dimer, 95 also had an etCO 2 /O 2 less than 0.28, including 33 who had PE, leading to a posterior probability of 33/95 or 34.7% (95% CI for the difference, 34.7223.2 5 11.5%, 1.6-22.4%). Second, when the 40 (8.1% of the cohort) patients who had a positive D-dimer but had an etCO 2 /O 2 greater than 0.45 were also considered test negative in addition to the 128 patients with a negative D-dimer (D-dimer , 500 ng/ml or etCO 2 /O 2 . 0.45), the proportion of patients with a negative combined test result was significantly increased to 168/495 or 34.0% (95% CI for difference of 8.1%, 5.8-10.8%), and six of these 168 patients had PE, all six of which were isolated subsegmental PE, resulting in a posterior probability for any PE equal to 6/168 or 3.8% (95% CI, 1.3-7.6%). Further details of these six patients include a D-dimer greater than 500 in three and an etCO 2 /O 2 greater than 0.45 in three; risk factors for PE of estrogen use (2), prior history of PE (1), and active malignancy (1); one patient with COPD; and none with DVT found on ultrasound. Table 3 shows the results of the per protocol analysis that restricts the criterion standard for PE(1) to the 60 (12.1%) patients with MDCTPA scans that demonstrated segmental or larger filling defects. For the detection of segmental or larger PE, the addition of the etCO 2 /O 2 to the D-dimer increased both the posterior probability of PE with a positive test result and the proportion of the cohort with a negative test result. Of the 367 patients with a positive D-dimer, 60 had segmental or larger PE, leading to a posterior probability of 16.3% (95% CI, 12.7-20.5%). Among the 95 with both a positive D-dimer and an etCO 2 /O 2 less than 0.28, 27/95 (28.4%) had segmental or larger PE, leading to a significantly increased posterior probability compared with the prevalence of segmental or larger PE in the entire cohort (95% CI for difference of 12.1%, 3.0-22.5%). None of the 128 patients with a negative D-dimer and none of the 53 patients with an etCO 2 /O 2 greater than 0.45 had a segmental or larger PE. Forty patients (8% of cohort) had D-dimer greater than 499 ng/ml but had etCO 2 /O 2 greater than 0.45. Thus, the incremental value of the etCO 2 /O 2 added to the D-dimer in terms of the number needed to test to prevent one MDCTPA was 12.3. In total, 168 patients had either the D-dimer less than 500 ng/ml or the etCO 2 /O 2 greater than 0.45, and none of these had segmental or larger PE. Thus, the posterior probability of segmental or larger PE in patients with the negative combined test(2) result (D-dimer , 500 ng/ml or etCO 2 /O 2 . 0.45) was 0/168 (95% CI, 0-2.2%).
Detection of Segmental or Larger PE
Detection of Subsegmental and Chronic PE
The baseline frequency of isolated subsegmental PE discovered on MDCTPA was 29/495 (5.8%). Had clinicians only ordered MDCTPA scanning for patients with a positive D-dimer, then the frequency of isolated subsegmental PE would have been 25/367 or 6.8%, and had they only ordered MDCTPA for patients with a positive D-dimer and an etCO 2 /O 2 less than 0.45, this frequency would have been 23/327 (7.0%). Among the four patients with chronic PE and no evidence of acute PE, the D-dimer was normal in one (350 ng/ml), and all four patients had an etCO 2 /O 2 less than 0.45.
Detection of Subsegmental PE with DVT
Of the 29 patients with subsegmental PE, 20 underwent venous ultrasonography of the legs (one included the arms as well) and 9 others underwent CT venography within 10 days of enrollment. Six patients had venous noncompressibility consistent with DVT in the following veins: one in a brachial vein distal to an indwelling catheter, two with isolated calf veins, and two with isolated popliteal veins; one had both chronic femoral and calf vein findings. All six of the patients with a positive ultrasound had both a D-dimer greater than 499 ng/ml and an etCO 2 /O 2 less than 0.45.
PE and DVT on Follow-up
Within 45 days, eight patients who did not have any PE diagnosis at enrollment had imaging performed as part of standard care that suggested new PE (n 5 2) or DVT (n 5 6) ( Table 4) . Three of these patients were prescribed anticoagulation at enrollment, but their compliance with treatment was not studied. Two of the 8 patients were prescribed new anticoagulation because of the imaging results.
DISCUSSION
This study tested the hypothesis that when compared with the D-dimer alone, the combination of D-dimer plus etCO 2 /O 2 could produce clinically important improvements as a screening strategy for segmental or larger PE before MDCTPA in a moderate risk population. The main finding was that the test-positive combination (D-dimer . 499 ng/ml and etCO 2 / O 2 , 0.28) produced a posterior probability of any PE equal to 34.7% and a posterior probability of segmental or larger PE equal to 28.4%, representing a significant increase over the posterior probability of PE observed with a positive D-dimer alone in either case. The second main finding was that no patient with a D-dimer less than 500 ng/ml and no patient with an etCO 2 For definition of abbreviations see Table 2 . * n 5 316 had an etCO 2 /O 2 of 0.28 to , 0.45, of whom 33 had segmental or larger PE and 283 had no PE or subsegmental PE. combination defined by a D-dimer less than 500 ng/ml or an etCO 2 /O 2 greater than 0.45. Alternatively, the presence of a Ddimer greater than 499 ng/ml and an etCO 2 /O 2 less than 0.28, together with a moderate to high clinical suspicion for PE, could be interpreted as sufficient evidence to initiate anticoagulation before imaging results, assuming the patient had no contraindications. The clinical importance of these data depends in part on the clinician's perception of the clinical significance of the isolated subsegmental PE, which is known to vary considerably among clinicians (5) . Published guidelines either imply that isolated subsegmental PE does not warrant anticoagulation, or remain silent on the issue, perhaps because of the lack of any outcomes data (10, 11, 24, 25) . We found that 29/89 (32.5%) of patients with an MDCTPA interpreted as having acute PE by either radiologist as having a total filling defect less than 5%, suggesting smaller than segmental PE (see online supplement). Our frequency of isolated subsegmental PE is higher than was reported by Brunot and colleagues in 2005, who found 9 of 75 (12%) patients with PE observed on MDCTPA had isolated subsegmental PE (6) .
This work adds to published data showing that the addition of the etCO 2 /O 2 to pretest probability can produce very good diagnostic accuracy in a lower-risk ED population (18) . In addition, the etCO 2 /O 2 may represent a novel method to monitor patients at high risk for PE who are about to engage in surgery, chemotherapy, or other stressors that predispose to PE. Kline and Hogg found that the relative preoperative to postoperative change in etCO 2 /O 2 was 1.6 6 20%, whereas the relative change in D-dimer was 234 6 292% for patients undergoing surgery believed to be high risk for VTE (26) .
We believe this study design was rigorous in several unique respects. The sample was multicenter. The enrollment methods were highly planned in advance (see clinicaltrials.gov). We designed the study to enroll a representative sample of patients undergoing MDCTPA in current practice. Although the majority of published studies of screening strategies for PE enrolled only outpatients, we included an equal balance of inpatients and ED patients. We submit that the primary effect of including inpatients was to reduce the test specificity of both the D-dimer and etCO 2 /O 2 , because inpatients may be more likely to have elevated D-dimer concentrations and abnormal pulmonary function than ambulatory patients. The inclusion criteria were designed to produce a population that was at moderate risk for PE. In addition to the requirement of an MDCTPA ordered as standard care, we restricted enrollment to those patients with explicitly documented signs or symptoms and at least one known risk factor for PE. This resulted in a significantly higher prevalence of any-size PE (18%; 95% CI, 15-22%) than the 8% prevalence we recently found in a large, multicenter sample of ED patients who enrolled on the basis of any test ordered for PE (27) . Recognizing the potential confounding effect of a very low prevalence of PE was a major reason for restricting the inclusion criteria to yield at least a moderate-risk population.
Limitations include the fact that this study only tests the hypothetical contribution of the etCO 2 /O 2 and does not test its real-time use as a diagnostic instrument. In particular, a validation study must be performed to test if anticoagulation can be safely withheld in patients with an etCO 2 /O 2 greater than 0.45. An important limitation to the potential diagnostic usefulness of the etCO 2 /O 2 ratio is that the majority of measurements, 316 (64%), were in an intermediate range (0.28 to , 0.45) and therefore may not be helpful to decision making. The optimal management of subsegmental PE also remains uncertain. Although we collected data required for various pretest probability scoring systems, including the Wells criteria, we elected to not include them. We collected pretest probability data after the decision was made to order MDCTPA-a decision often made by a clinical team. We submit that pretest probability data need to be collected from the individual most responsible for ordering the MDCTPA. However, in 40% of enrolled patients, the research team was unable to determine the individual clinician willing to take primary responsibility for ordering the MDCTPA. Although we did perform detailed follow-up of all patients out to 45 days, we did not include recurrent venous thrombotic events in the criterion standard in this analysis.
In summary, this study found that the addition of an etCO 2 / O 2 less than 0.28 to a positive D-dimer significantly increases the probability of a filling defect consistent with a segmental or larger PE observed on MDCTPA, and that patients with either a negative D-dimer or an etCO 2 /O 2 greater than 0.45 had a very low probability of segmental or larger PE on MDCTPA. We conclude that the combined testing strategy of the D-dimer plus the etCO2 produces clinically important advantages as a screening step before MDCTPA compared with the D-dimer alone.
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